Central Nervous System Disorders is under clinical development by Neuroplast and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase I drugs for Amyotrophic Lateral Sclerosis have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Central Nervous System Disorders’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Central Nervous System Disorders overview
Stem cell therapy is under development for the treatment of traumatic spinal cord injury, amyotrophic lateral sclerosis, FTD, traumatic brain injury, spinal cord injuries and paraplegia. It is administered by intrathecal route. The therapeutic candidate comprises of autologous neuro-cells. It is based on Neuro-Cells technology platform.
Neuroplast overview
Neuroplast is a medical biotechnology company that develops regenerative medicine. It develops therapies and products for the treatment of acute and chronic idiopathic, traumatic and ischemic neurodegenerative disorders. Neuroplast is headquartered in Geleen, Limburg, the Netherlands.
For a complete picture of Central Nervous System Disorders’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
